安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Capstan Therapeutics
Unleashing the power of in vivo RNA therapieswith our CellSeeker™ targeted lipid nanoparticle (tLNP) platform technology
- P Hours after R N S N t e N 60 N t e N T o c t e A Novel Product . . .
Capstan’s proprietary lipid nanoparticle is a non-viral dose-tunable system designed for 1 25:1 5000 ll in vivo dosing
- Company - Capstan Therapeutics
We are a diverse team of experts integrating advancements in CAR-T therapy, mRNA, and LNPs, with rigorous focus to engineer transformative medicines
- Capstan Therapeutics to Present Preclinical Data on Lead In Vivo . . .
SAN DIEGO, September 26, 2024 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using CellSeeker™, a targeted lipid nanoparticle (tLNP) technology platform,
- Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T . . .
SAN DIEGO, November 18, 2024 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced preclinical data
- Capstan Therapeutics Announces $175M Oversubscribed Series B Financing . . .
– Financing syndicate led by RA Capital Management includes new investors Forbion, Johnson Johnson Innovation – JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments – Financing supports advancement of
- Capstan Therapeutics Launches with $165 Million to Deliver on the . . .
– Capstan’s foundation is built on research developed by world-renowned mRNA and cell therapy scientists and clinicians at the University of Pennsylvania – Therapy development focused on cell type-specific engineering
- 1500 Profound B Cell Depletion and Repopulation with Predominantly . . .
1500 Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Ep Ep Ep Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR 1000
|
|
|